1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Market Access Impact (US) [HIV]

Market Access Impact (US) [HIV]

  • April 2017
  • ID: 4883731
  • Format: PDF
  • By Firstword Pharma


Table of Contents

Are US market barriers helping or hindering your HIV brand?

Today’s tightly packed US HIV drug landscape is the culmination of numerous innovative developments over the last three decades. New market entrants continue to arrive – the most recent from Gilead – hoping to disrupt the status quo. But how are market barriers impacting prescribing choices, and what effect does that have on market share? Are newer players changing market dynamics?

Use this latest report to understand the barriers driving market share shifts. Market Access Impact: HIV (US) features 10 big-hitter HIV drugs from Gilead, Janssen Biotech, Merck & Co, BMS and ViiV Healthcare.

Top Takeaways
- One step ahead: Some brands gain advantage when competitors have not made it on to the formulary. But which single brand benefits the most?
- Visibility isn’t the problem: The proportion of physicians claiming not to know about these 10 HIV brands is negligible. With such high awareness, what else is impacting prescribing behaviour?
- It’s not plain sailing for some: Some drugs have very few prescribing barriers, however 1 in 6 physicians say this drug has 3 or more barriers. Which drug?
- The devil is in the detail: 14% of US prescribing decisions are affected by market barriers, but no single barrier stands out from the rest. Find out how to fine tune strategy in a tight-knit market.
- New kids on the block: How does prescribing of recent market entrants compare to more established drugs? Which market barriers are already associated with Descovy and Genvoya?

Insight into 10 Major HIV Drugs
- Descovy (emtricitabine/tenofovir alafenamide; Gilead)
- Genvoya (cobicistat/elvitegravir/emtricitabine/tenofovir alafenamide; Gilead)
- Isentress (raltegravir; Merck & Co.)
- Prezcobix (darunavir/cobicistat; Janssen Biotech)
- Prezista (darunavir; Janssen Biotech)
- Reyataz (atazanavir; BMS)
- Stribild (cobicistat/elvitegravir/emtricitabine/tenofovir disoproxil fumarate; Gilead)
- Triumeq (abacavir/dolutegravir/lamivudine; ViiV Healthcare)
- Truvada (emtricitabine/tenofovir disoproxil fumarate; Gilead)
- Viread (tenofovir disoproxil fumarate; Gilead)

Lifting the lid on Market Access issues
Market Access Impact: HIV gives a unique insight into the issues affecting the major HIV drug manufacturers.

You’ll learn:
How barriers affect market access:
- Which HIV brands are physicians prescribing the most?
- How are prescribing decisions being affected by market barriers?
- Are some barriers having more impact than others?

How barriers affect your brand:
- How many doctors prescribe your brand? How many don’t, but would consider it?
- Why don’t doctors prescribe your brand? What do they choose instead?
- Which competing brands does your brand take market share from?

A Report Based on Expert Knowledge
We surveyed 100 infectious disease specialists and general practitioners in the US.

All respondents have:
- Been practising for 2+ years
- Prescribed at least one of the listed products
- Seen at least 5 HIV patients in total in the last month

We conducted the survey between 2nd and 7th March 2017.

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Cyclin Dependent Kinase 9 - Pipeline Review, H2 2019

Cyclin Dependent Kinase 9 - Pipeline Review, H2 2019

  • $ 3500
  • December 2019

Cyclin Dependent Kinase 9 - Pipeline Review, H2 2019SummaryCyclin Dependent Kinase 9 (Tat Associated Kinase Complex Catalytic Subunit or C 2K or Cell Division Cycle 2 Like Protein Kinase 4 or Cell Division ...

C-C Chemokine Receptor Type 5 - Pipeline Review, H2 2019

C-C Chemokine Receptor Type 5 - Pipeline Review, H2 2019

  • $ 3500
  • November 2019

C-C Chemokine Receptor Type 5 - Pipeline Review, H2 2019SummaryAccording to the recently published report ’C-C Chemokine Receptor Type 5 - Pipeline Review, H2 2019’; C-C Chemokine Receptor Type 5 (CHEMR13 ...

Cytomegalovirus (HHV-5) Infections Global Clinical Trials Review, H1, 2020

Cytomegalovirus (HHV-5) Infections Global Clinical Trials Review, H1, 2020

  • $ 2500
  • January 2020

Cytomegalovirus (HHV-5) Infections Global Clinical Trials Review, H1, 2020Summaryclinical trial report, “Cytomegalovirus (HHV-5) Infections Global Clinical Trials Review, H1, 2020" provides an overview ...


Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on